Blog
RSS FeedPosted by Michael Wonder on 14 Jul 2023
Health Canada approves Lynparza in combination with abiraterone and prednisone or prednisolone for patients with BRCA mutated metastatic castration-resistant prostate cancer
13 July 2023 - Conditional approval based on data from Phase 3 PROpel trial. ...
Posted by Michael Wonder on 26 Jul 2017
Health Canada approves Adcetris (brentuximab vedotin) for the post-ASCT consolidation treatment of patients with Hodgkin lymphoma at increased risk of relapse or progression
25 July 2017 - Approval based on positive phase 3 AETHERA clinical trial results. ...